Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer

Martin August Voss(Cheltenham General Hospital), Sudha Sundar(Sandwell & West Birmingham Hospitals NHS Trust)
British Journal of Cancer
April 19, 2011
10.1038/bjc.2011.80
Cited by 63

Related Papers

ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
|Annals of Oncology|2024|277
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
|The Lancet|2019|223
ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis
|Annals of Oncology|2017|51
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
|The Lancet Oncology|2022|45
Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment
|Annals of Oncology|2018|5